Contributions
Abstract: EP1614
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Secukinumab is a monoclonal antibody fully human anti-human interleukin-17A (IL-17A) that neutralizes the bioactivity of human IL-17A. Secukinumab is used in autoinmune disseases like psoriasis and rheumatoid arthritis. There is evidence on the role of IL17 in the pathogenesis of multiple sclerosis, and there is clinical evidence of safe, well-tolerated, and significantly reduced MRI lesion activity through a phase II study
Objectives: To describe two clinical cases of patients with Multiple Sclerosis treated with Secukinumab
Metarial and methods: We present two cases of patients with Multiple Sclerosis treated with Secukinumab and affected by other autoimmune pathologies. The treatment decision is made through multidisciplinary management.
Results: Patient1. A 22-years-old man with B27 positive seronegative polyarthritis who develops an aggressive multiple sclerosis after the use of anti-TNF. The patient, who was treated for a year with Tozilizumab and Metotrexate with poor response in both diseases, is currently free of neurological and rheumatic disease after a 3 years treatment with Secukinumab.
Patient 2. A 23-years-old woman affected by undifferentiated spondyloarthropathy HLAB27 negative with insufficient response to Salazopyrin, Motrexate and Golimumab, who starts aggressive Multiple Sclerosis and who has been stable after a 8 months treatment with Secukinumab.
None of the patients presented adverse side effects to the treatment.
Conclusions: Secukinumab might be a good therapeutic alternative in multiple sclerosis patients with rheumatological comorbidities, and allows effective management without adverse effects and without the need for concomitant immunosuppression. Multidisciplinary management is essential in these cases
Disclosure: Virginia Meca-Lallana disclose neither conflict of interest in the elaboration of this abstract
Abstract: EP1614
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Secukinumab is a monoclonal antibody fully human anti-human interleukin-17A (IL-17A) that neutralizes the bioactivity of human IL-17A. Secukinumab is used in autoinmune disseases like psoriasis and rheumatoid arthritis. There is evidence on the role of IL17 in the pathogenesis of multiple sclerosis, and there is clinical evidence of safe, well-tolerated, and significantly reduced MRI lesion activity through a phase II study
Objectives: To describe two clinical cases of patients with Multiple Sclerosis treated with Secukinumab
Metarial and methods: We present two cases of patients with Multiple Sclerosis treated with Secukinumab and affected by other autoimmune pathologies. The treatment decision is made through multidisciplinary management.
Results: Patient1. A 22-years-old man with B27 positive seronegative polyarthritis who develops an aggressive multiple sclerosis after the use of anti-TNF. The patient, who was treated for a year with Tozilizumab and Metotrexate with poor response in both diseases, is currently free of neurological and rheumatic disease after a 3 years treatment with Secukinumab.
Patient 2. A 23-years-old woman affected by undifferentiated spondyloarthropathy HLAB27 negative with insufficient response to Salazopyrin, Motrexate and Golimumab, who starts aggressive Multiple Sclerosis and who has been stable after a 8 months treatment with Secukinumab.
None of the patients presented adverse side effects to the treatment.
Conclusions: Secukinumab might be a good therapeutic alternative in multiple sclerosis patients with rheumatological comorbidities, and allows effective management without adverse effects and without the need for concomitant immunosuppression. Multidisciplinary management is essential in these cases
Disclosure: Virginia Meca-Lallana disclose neither conflict of interest in the elaboration of this abstract